Role of GPR40 in pathogenesis and treatment of Alzheimer's disease and type 2 diabetic dementia

J Drug Target. 2019 Apr;27(4):347-354. doi: 10.1080/1061186X.2018.1491979. Epub 2018 Jul 24.

Abstract

G-protein coupled receptor 40 (GPR40) is also known as free fatty acid receptor 1. It is a typical 7 transmembrane receptor and currently the natural receptor of the saturated or unsaturated long-chain fatty acids. It could trigger the intracellular signalling pathway when combined with the free long-chain fatty acids, thereby controlling cells physiological function. In this review, we summarised the relationships and the potential mechanisms between the promising target GPR40, and pathogenesis and treatment of Alzheimer's disease and type 2 diabetic dementia. It may provide a theoretical reference for the development of clinical drug targeting GPR40.

Keywords: Alzheimer's disease; G-protein coupled receptor 40; phospholipase C; protein kinase B; type 2 diabetic dementia.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / drug therapy
  • Alzheimer Disease / physiopathology*
  • Animals
  • Dementia / drug therapy
  • Dementia / physiopathology*
  • Diabetes Mellitus, Type 2 / complications*
  • Diabetes Mellitus, Type 2 / drug therapy
  • Drug Development
  • Humans
  • Receptors, G-Protein-Coupled / metabolism*
  • Signal Transduction

Substances

  • FFAR1 protein, human
  • Receptors, G-Protein-Coupled